Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the safety and tolerability of VX-809 in
participants with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF
transmembrane conductance regulator (CFTR) gene.